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TNF blockade has been successful in the treatment of some rheumatic diseases such as
spondyloarthritis. Many infectious complications have been reported with anti-TNF therapy,
mainly bacterial, mycobacterial, viral and fungal infections. Entamoeba histolytica is an extra-
cellular protozoan parasite that mainly causes colitis and hepatic abscess; bowel perforation
is  an uncommon complication with high mortality. TNF is considered the principal mediator
of  cell immunity against amebiasis. Initially, it is chemotactic to E. histolytica, enhancing its
adherence to enterocyte via galactose inhibitable lectin, and then activating macrophages
to  kill ameba though the release of NO, so that TNF blocking could be harmful, increasing
amebic virulence. We  describe the case of a 46-year-old woman with spondyloarthritis who
presented a colonic perforation due to invasive amebic colitis during anti-TNF use.
© 2014 Elsevier Editora Ltda. All rights reserved.
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O bloqueio do TNF tem tido sucesso no tratamento de algumas doenc¸as reumáticas, como a
espondiloartrite. Relatam-se muitas complicac¸ões infecciosas com a terapia anti-TNF, prin-
cipalmente infecc¸ões bacterianas, micobacterianas, virais e fúngicas. A Entamoeba histolyticaé  um protozoário extracelular que causa principalmente colite e abscesso hepático, sendo
estinal é uma complicac¸ão rara, com alta mortalidade. O TNF é con-que  a perfurac¸ão intsiderado o principal mediador da imunidade celular contra a amebíase. Inicialmente, é
quimiotático para a E. histolytica, potencializando sua adesão ao enterócito por meio da
lectina galactose-inibível, e depois ativando os macrófagos para matarem a ameba pela
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liberac¸ão de NO; assim, o bloqueio do TNF poderia ser prejudicial, aumentando a virulên-
cia  amebiana. Descreve-se o caso de uma mulher de 46 anos com espondiloartrite que
apresentou uma perfurac¸ão do colo por colite amebiana invasiva durante uso de anti-TNF.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.
Figure 1 – Histological examination of the resected colon
in vitro toxicity against E histolytica trophozoites and its
production is increased by TNF.9 Macrophages isolated from
amoebic liver granulomas are defective for the production ofIntroduction
TNF (tumoral necrosis factor) is a major cytokine involved in
the pathogenesis of rheumatoid arthritis and spondyloarthri-
tis. TNF inhibitors have been showed to be effective in the
treatment of axial and peripheral spondyloarthritis and in
some extraarticular manifestations, however some infectious
complications have been reported. These included bacterial,
mycobacterial, viral and fungal infection. Amebic infection
has not been described during anti-TNF inhibitor. We describe
a 46-year-old woman with spondyloarthritis who presented a
colonic perforation due to invasive amebic colitis during anti-
TNF use.
Case  report
A 46-year-old female with a previous diagnosis of spondy-
loarthritis based on ASAS criteria,1 who was been treated
with subcutaneous adalimumab 40 mg  every other week dur-
ing 4 months and good disease control activity. She presented
diffuse abdominal pain and mucous diarrhea for 2 weeks.
Physical exam revealed distended abdomen without bowel
sounds and diffuse rebound tenderness, so a diagnosis of
acute peritonitis was done. Laboratory tests gave the following
results: leucocyte count: 11.980/mm3 with 73% of neutrophils,
hemoglobin: 9.6 gr/dL, CRP: 55 mgr/L. Emergency laparotomy
showed multiple and small colonic perforations and severe
peritonitis; right hemicolectomy, mucous ﬁstula of ileon
and intraperitoneal drainage were performed. Metronidazole,
ertapenem, teclozan were administered during her hospital-
ization in intensive care unit. Histopathological examination
of the resected gut revealed extensive areas of ulceration with
abundant trophozoites of E histolytica (Figs. 1 and 2). One
month later the patient was discharged without other com-
plication. At this time the patient is being medicated with
naproxen 250 mgr  BID with partial response, while ileostomy
closure is done to resume adalimumab.
Discussion
Entamoeba histolytica is an extracellular protozoan para-
site that causes mainly colitis and hepatic abscess and it is
responsible of 100.000 deaths worldwide every year. Bowel per-
foration occurs between 1%-6% of the patients with amebiasis
but its mortality is extremely high ranging from 55% to 100%.2TNF plays an important role in the pathogenesis of
parasitic infection3,4 and it is considered the principal medi-
ator of cell immunity against amebiasis. Gamma  interferon,
colony-stimulating factor 1 act synergistically with TNF indemonstrated extensive mucosal ulceration.
macrophage activation using a murine mode.5 TNF produced
by macrophages can kill E histolytica in vitro.6
Oppositely, Blasquez et al demonstrated that TNF
can enhance amebic virulence and is chemotactic for E
histolytica.7 Amebic adherence to colonic mucosa is medi-
ated by galactose inhibitable lectin8 which is a potent
stimulant of TNF production. Nitric oxid (NO) is a major
effector molecule produced by activated macrophages forFigure 2 – High power view of trophozoites of E histolytica
in right colon (40×).
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NF,10 NO,11 H2O2.12 Finally anti-TNF antibodies inhibit TNF
elease, NO production, and amebicidal activity by actived
urine macrophages.13
In conclusion TNF has a dual role, initially is chemotac-
ic to E histolytica, enhancing its adherence to enterocyte via
alactose inhibitable lectin and then activating macrophages
o kill ameba  though the release NO so that TNF block-
ng could be harmful increasing amebic virulence. From our
nowledge this is the ﬁrst case of colonic perforation due to
nvasive amebic colitis during anti-TNF therapy. We  recom-
end deworming against E histolytica in endemic areas prior
he beginning of anti-TNF therapy and regularly during its use.
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